Drugs & Therapy Perspectives

, Volume 18, Issue 10, pp 1–4 | Cite as

Tamsulosin offers advantages over other α1-adrenoceptor antagonists in the treatment of LUTS

New Drugs and Profile Reports


Benign Prostatic Hyperplasia Lower Urinary Tract Symptom Finasteride International Prostate Symptom Score Tamsulosin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lyseng-Williamson KA, Jarvis B, Wagstaff AJ. Tamsulosin: an update of its role in the management of lower urinary tract symptoms. Drugs 2002; 62 (1): 135–67PubMedCrossRefGoogle Scholar
  2. 2.
    Dunn CJ, Matheson A, Faulds DM. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging 2002; 19 (2): 135–61PubMedCrossRefGoogle Scholar
  3. 3.
    Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993 Jul; 150: 85–9PubMedGoogle Scholar
  4. 4.
    Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991 Aug 24; 338: 469–71PubMedCrossRefGoogle Scholar
  5. 5.
    McConnell JD, Barry MJ, Bruskewitz RC, et al. Benign prostatic hyperplasia: diagnosis and treatment. Clinical Practice Guidelines No. 8. Rockville (MD): Agency for Health Care Policy and Research, Public Health Service, US Dept. of Health and Human Services, 1994Google Scholar
  6. 6.
    Roehrborn CG. The Agency for Health Care Policy and Research. Clinical guidelines for the diagnosis and treatment of benign prostatic hyperplasia. Urol Clin North Am 1995 May; 22 (2): 445–53PubMedGoogle Scholar
  7. 7.
    Fowler Jr FJ, Wennberg JE, Timothy RP, et al. Symptom status am quality of life following prostatectomy. JAMA 1988; 259: 3018–22PubMedCrossRefGoogle Scholar
  8. 8.
    Chapple CR. Real-life experience in lower urinary tract symptom management. Drugs Today 2001; 37 Suppl. D: 47–9Google Scholar
  9. 9.
    Boyle P, Gould L, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398–405PubMedCrossRefGoogle Scholar
  10. 10.
    Abrams P, Schulman CC, Vaage S, et al. Tamsulosin, a selective α1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH). European Tamsulosin Study Group. Br J Urol 1995; 76: 325–36PubMedCrossRefGoogle Scholar
  11. 11.
    Narayan P, Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J Urol 1998; 160: 1701–6PubMedCrossRefGoogle Scholar
  12. 12.
    Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998; 51: 892–900PubMedCrossRefGoogle Scholar
  13. 13.
    Schulman CC, Lock TM, Buzelin J-M, et al. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. Urology 2001 Oct; 166: 1358–63CrossRefGoogle Scholar
  14. 14.
    Buzelin JM, Fonteyne E, Kontturi M, et al. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). European Tamsulosin Study Group. Br J Urol 1997; 80: 597–605PubMedCrossRefGoogle Scholar
  15. 15.
    Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 1–13PubMedCrossRefGoogle Scholar
  16. 16.
    Boehringer Ingelheim Pharmaceuticals Incorporated. Flomax (tamsulosin) prescribing information. Ridgefield (CT): Boehringer Ingelheim, 2000Google Scholar
  17. 17.
    Yamanouchi Pharmaceutical Co. Ltd. Harnal (tamsulosin) prescribing information. Tokyo: Yamanouchi Pharmaceutical Co. Ltd., 2000 JanGoogle Scholar
  18. 18.
    Yamanouchi Europe B.V. Tamsulosin: a summary of product characteristics (SmPC). Leiderdorp, The Netherlands: Yamanouchi Europe B.V., 1998 May 27Google Scholar
  19. 19.
    Beduschi R, Beduschi MC, Oesterling JE. Benign prostatic hyperplasia: use of drug therapy in primary care. Geriatrics 1998; 53: 24–8, 33-4, 37-40PubMedGoogle Scholar
  20. 20.
    Cooper KL, McKiernan JM, Kaplan SA. α1-Adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. Drugs 1999; 48: 398–405Google Scholar

Copyright information

© Adis International Limited 2002

Personalised recommendations